Prospective Randomized Clinical Trial Comparing Paclitaxel-Coated Balloon Versus Conventional Balloon Angioplasty in Treating Below the Knee Arterial Lesions in Chronic Limb Threatening Ischemia: The CRURAL DEB Study
Restricted accessResearch articleFirst published online 2025
Prospective Randomized Clinical Trial Comparing Paclitaxel-Coated Balloon Versus Conventional Balloon Angioplasty in Treating Below the Knee Arterial Lesions in Chronic Limb Threatening Ischemia: The CRURAL DEB Study
Drug-coated balloons (DCB) might improve the results of below the knee (BTK) angioplasty, but sufficient randomized data comparing DCB and conventional angioplasty in treating patients with chronic limb threatening ischemia (CLTI) are lacking. This study aimed to perform a randomized comparison between a paclitaxel-coated angioplasty balloon catheter and a conventional balloon angioplasty catheter in treating BTK arterial lesions.
Patients presenting with CLTI scheduled for endovascular treatment of BTK arterial lesions were assigned to DCB or conventional angioplasty. The primary endpoint was primary patency at 12 months. Secondary endpoints were target lesion revascularization (TLR), technical success, clinical success, amputation free survival (AFS), and serious adverse events.
Results:
A total of 64 CLTI patients, 70 limbs, and 122 lesions were enrolled, with 35 limbs in each group. Demographics, comorbidities, and Rutherford class were similar in both treatment arms. The rates of chronic total occlusions were 81% and 89% (NS) in the DCB and control group, respectively, with corresponding median lesion lengths of 150 and 100 mm (NS) in the two groups. No significant differences were detected between groups regarding primary limb patency (hazard ratio [HR]=0.64, p=0.24, confidence interval [CI]=0.30-1.35).
Conclusions:
This single-center prospective randomized study could not demonstrate superiority of DCB compared with conventional balloon angioplasty regarding the primary endpoint, as primary patency, when treating BTK arterial lesions in patients with CLTI.
Clinical Impact
This randomised trial aims to pragmatically investigate whether there is a clinically relevant difference between drug eluting angioplasty and standard plain old balloon angioplasty in treating below the knee arterial lesions in subjects with chronic limb threatening ischemia. Regarding the primary endpoint variable, the study was not able to reveal a significant DCB superiority in primary patency.
AgnelliGBelchJJFBaumgartnerI, et al. Morbidity and mortality associated with atherosclerotic peripheral artery disease: a systematic review. Atherosclerosis. 2020;293:94–100. doi:10.1016/j.atherosclerosis.2019.09.012.
2.
BoyleJPHoneycuttAANarayanKM, et al. Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the U.S. Diabetes Care. 2001;24(11):1936–1940. doi:10.2337/diacare.24.11.1936.
3.
CreagerMAMatsushitaKAryaS, et al. Reducing nontraumatic lower-extremity amputations by 20% by 2030: time to get to our feet: a policy statement from the American heart association. Circulation. 2021;143(17):e875–e891. doi:10.1161/CIR.0000000000000967.
4.
DuffSMafiliosMSBhounsuleP, et al. The burden of critical limb ischemia: a review of recent literature. Vasc Health Risk Manag. 2019;15:187–208. doi:10.2147/VHRM.S209241.
5.
FagliaEClericiGClerissiJ, et al. Long-term prognosis of diabetic patients with critical limb ischemia: a population-based cohort study. Diabetes Care. 2009;32(5):822–827. doi:10.2337/dc08-1223.
6.
RollinsKEJacksonDCoughlinPA.Meta-analysis of contemporary short- and long-term mortality rates in patients diagnosed with critical leg ischaemia. Br J Surg. 2013;100(8):1002–1008. doi:10.1002/bjs.9127.
7.
SogaYIidaOTakaharaM, et al. Two-year life expectancy in patients with critical limb ischemia. JACC Cardiovasc Interv. 2014;7(12):1444–1449. doi:10.1016/j.jcin.2014.06.018.
8.
SigvantBHasvoldPKragstermanB, et al. Cardiovascular outcomes in patients with peripheral arterial disease as an initial or subsequent manifestation of atherosclerotic disease: results from a Swedish nationwide study. J Vasc Surg. 2017;66(2):507–514. doi:10.1016/j.jvs.2017.01.067.
9.
SigvantBLundinFWahlbergE.The risk of disease progression in peripheral arterial disease is higher than expected: a meta-analysis of mortality and disease progression in peripheral arterial disease. Eur J Vasc Endovasc Surg. 2016;51(3):395–403. doi:10.1016/j.ejvs.2015.10.022.
10.
Abu DabrhAMSteffenMWUndavalliC, et al. The natural history of untreated severe or critical limb ischemia. J Vasc Surg. 2015;62(6):1642–1651. doi:10.1016/j.jvs.2015.07.065.
11.
SpreenMIGremmelsHTeraaM, et al. Diabetes is associated with decreased limb survival in patients with critical limb ischemia: pooled data from two randomized controlled trials. Diabetes Care. 2016;39(11):2058–2064. doi:10.2337/dc16-0850.
12.
AboyansVRiccoJBBartelinkMEL, et al. 2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European society for vascular surgery (ESVS): document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries endorsed by: the European stroke organization (ESO) the task force for the diagnosis and treatment of peripheral arterial diseases of the European society of cardiology (ESC) and of the European society for vascular surgery (ESVS). Eur Heart J. 2018;39(9):763–816. doi:10.1093/eurheartj/ehx095.
13.
BaileySRBeckmanJADaoTD, et al. ACC/AHA/SCAI/SIR/SVM 2018 appropriate use criteria for peripheral artery intervention: a report of the American college of cardiology appropriate use criteria task force, American heart association, society for cardiovascular angiography and interventions, society of interventional radiology, and society for vascular medicine. J Am Coll Cardiol. 2019;73(2):214–237. doi:10.1016/j.jacc.2018.10.002.
14.
Gerhard-HermanMDGornikHLBarrettC, et al. 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. J Am Coll Cardiol. 2017;69(11):e71–e126. doi:10.1016/j.jacc.2016.11.007.
15.
BisdasTBorowskiMStavroulakisK, et al. Endovascular therapy versus bypass surgery as first-line treatment strategies for critical limb ischemia: results of the interim analysis of the CRITISCH registry. JACC Cardiovasc Interv. 2016;9(24):2557–2565. doi:10.1016/j.jcin.2016.09.039.
16.
BradburyAWMoakesCAPopplewellM, et al. A vein bypass first versus a best endovascular treatment first revascularisation strategy for patients with chronic limb threatening ischaemia who required an infra-popliteal, with or without an additional more proximal infra-inguinal revascularisation procedure to restore limb perfusion (BASIL-2): an open-label, randomised, multicentre, phase 3 trial. Lancet. 2023;401(10390):1798–1809. doi:10.1016/s0140-6736(23)00462-2.
17.
GentileFLundbergGHultgrenR.Outcome for endovascular and open procedures in infrapopliteal lesions for critical limb ischemia: registry based single center study. Eur J Vasc Endovasc Surg. 2016;52(5):643–649. doi:10.1016/j.ejvs.2016.07.013.
18.
CasellaIBSartoriCHFaustinoCB, et al. Endovascular therapy provides similar results of bypass graft surgery in the treatment of infrainguinal multilevel arterial disease in patients with chronic limb-threatening ischemia in All GLASS stages. Ann Vasc Surg. 2020;68:400–408. doi:10.1016/j.avsg.2020.04.028.
19.
BosiersMHartJPDelooseK, et al. Endovascular therapy as the primary approach for limb salvage in patients with critical limb ischemia: experience with 443 infrapopliteal procedures. Vascular. 2006;14(2):63–69. doi:10.2310/6670.2006.00014.
20.
MohapatraAHenryJCAvgerinosED, et al. Bypass versus endovascular intervention for healing ischemic foot wounds secondary to tibial arterial disease. J Vasc Surg. 2018;68(1):168–175. doi:10.1016/j.jvs.2017.10.076.
21.
ConteMSBradburyAWKolhP, et al. Global vascular guidelines on the management of chronic limb-threatening ischemia. Eur J Vasc Endovasc Surg. 2019;58(1S):S1–S109. doi:10.1016/j.ejvs.2019.05.006.
22.
GrayBHDiaz-SandovalLJDieterRS, et al. SCAI expert consensus statement for infrapopliteal arterial intervention appropriate use. Catheter Cardiovasc Interv. 2014;84(4):539–545. doi:10.1002/ccd.25395.
23.
ShishehborMHWhiteCJGrayBH, et al. Critical limb ischemia: an expert statement. J Am Coll Cardiol. 2016;68(18):2002–2015. doi:10.1016/j.jacc.2016.04.071.
24.
MustaphaJAFintonSMDiaz-SandovalLJ, et al. Percutaneous transluminal angioplasty in patients with infrapopliteal arterial disease. Circ Cardiovasc Interv. 2016;9(5):e003468. doi:10.1161/CIRCINTERVENTIONS.115.003468.
25.
SchmidtAUlrichMWinklerB, et al. Angiographic patency and clinical outcome after balloon-angioplasty for extensive infrapopliteal arterial disease. Catheter Cardiovasc Interv. 2010;76(7):1047–1054. doi:10.1002/ccd.22658.
26.
FukunagaMKawasakiDNishimuraM, et al. Clinical effects of planned endovascular therapy for critical limb ischemia patients with tissue loss. J Atheroscler Thromb. 2019;26(3):294–301. doi:10.5551/jat.45344.
27.
LiistroFWeinbergIPopmaAA, et al. Paclitaxel-coated balloons versus percutaneous transluminal angioplasty for infrapopliteal chronic total occlusions: the IN.PACT BTK randomised trial. Eurointervention. 2022;17(17):E1445–E1454. doi:10.4244/EIJ-D-21-00444.
28.
LiistroFRecciaMRAngioliP, et al. Drug-eluting balloon for below the knee angioplasty: five-year outcome of the DEBATE-BTK randomized clinical trial. Cardiovasc Intervent Radiol. 2022;45(6):761–769. doi:10.1007/s00270-022-03104-3.
29.
LiistroFAngioliPVentoruzzoG, et al. Randomized controlled trial of acotec drug-eluting balloon versus plain balloon for below-the-knee angioplasty. JACC Cardiovasc Interv. 2020;13(19):2277–2286. doi:10.1016/j.jcin.2020.06.045.
30.
SpreenMIMartensJMKnippenbergB, et al. Long-term follow-up of the PADI trial: percutaneous transluminal angioplasty versus drug-eluting stents for infrapopliteal lesions in critical limb ischemia. J Am Heart Assoc. 2017;6(4):e004877. doi:10.1161/JAHA.116.004877.
31.
SpreenMIMartensJMHansenBE, et al. Percutaneous transluminal angioplasty and drug-eluting stents for infrapopliteal lesions in critical limb ischemia (PADI) trial. Circ Cardiovasc Interv. 2016;9(2):e002376. doi:10.1161/CIRCINTERVENTIONS.114.002376.
32.
KatsanosKSpiliopoulosSDiamantopoulosA, et al. Wound healing outcomes and health-related quality-of-life changes in the ACHILLES trial: 1-year results from a prospective randomized controlled trial of infrapopliteal balloon angioplasty versus sirolimus-eluting stenting in patients with ischemic peripheral arterial disease. JACC Cardiovasc Interv. 2016;9(3):259–267. doi:10.1016/j.jcin.2015.10.038.
33.
ZellerTBeschornerUPilgerE, et al. Paclitaxel-coated balloon in infrapopliteal arteries: 12-month results from the BIOLUX P-II randomized trial (BIOTRONIK’S-first in man study of the passeo-18 LUX drug releasing PTA balloon catheter vs. the uncoated passeo-18 PTA balloon catheter in subjects requiring revascularization of infrapopliteal arteries). JACC Cardiovasc Interv. 2015;8(12):1614–1622. doi:10.1016/j.jcin.2015.07.011.
34.
SmithJASoKLKashyapVS, et al. Outcome after revascularization with paclitaxel-coated devices in patients with chronic limb-threatening ischemia. J Vasc Surg. 2023;77(6):1742–1750. doi:10.1016/j.jvs.2023.01.195.
35.
KuminsNHKingAHAmbaniRN, et al. Paclitaxel-coated peripheral arterial devices are associated with improved overall survival and limb salvage in patients with chronic limb-threatening ischemia. J Vasc Surg. 2021;74(5):1682–1688. doi:10.1016/j.jvs.2021.05.035.
36.
PhairJCarnevaleMLipsitzEC, et al. Amputation-free survival in patients with critical limb ischemia treated with paclitaxel-eluting stents and paclitaxel-coated balloons. Ann Vasc Surg. 2020;62:8–14. doi:10.1016/j.avsg.2019.05.013.
37.
MustaphaJABrodmannMGeraghtyPJ, et al. Drug-coated vs uncoated percutaneous transluminal angioplasty in infrapopliteal arteries: six-month results of the lutonix BTK trial. J Invasive Cardiol. 2019;31(8):205–211.
38.
BarbarawiMQaziAHLeeJ, et al. Meta-analysis comparing drug-coated balloons and percutaneous transluminal angioplasty for infrapopliteal artery disease. Am J Cardiol. 2022;183:115–121. doi:10.1016/j.amjcard.2022.08.007.
39.
TepeGWangJCorpatauxJM, et al. BIOLUX P-III passeo-18 lux all-comers registry: 24-month results in below-the-knee arteries. Cardiovasc Intervent Radiol. 2021;44(1):10–18. doi:10.1007/s00270-020-02586-3.
40.
KonijnLCDWakkieTSpreenMI, et al. 10-year paclitaxel dose-related outcomes of drug-eluting stents treated below the knee in patients with chronic limb-threatening ischemia (The PADI trial). Cardiovasc Intervent Radiol. 2020;43(12):1881–1888. doi:10.1007/s00270-020-02602-6.
41.
NordanstigJJamesSAnderssonM, et al. Mortality with paclitaxel-coated devices in peripheral artery disease. N Engl J Med. 2020;383(26):2538–2546. doi:10.1056/NEJMoa2005206.
42.
PatelAIraniFGPuaU, et al. Randomized controlled trial comparing drug-coated balloon angioplasty versus conventional balloon angioplasty for treating below-the-knee arteries in critical limb ischemia: the SINGA-PACLI trial. Radiology. 2021;300(3):715–724. doi:10.1148/radiol.2021204294.
43.
KatsanosKSpiliopoulosSTeichgräberU, et al. Risk of major amputation following application of paclitaxel coated balloons in the lower limb arteries: a systematic review and meta-analysis of randomised controlled trials. Eur J Vasc Endovasc Surg. 2022;63:60–71. doi:10.1016/j.ejvs.2021.05.027.
44.
ZellerTBaumgartnerIScheinertD, et al. Drug-eluting balloon versus standard balloon angioplasty for infrapopliteal arterial revascularization in critical limb ischemia: 12-month results from the IN.PACT DEEP randomized trial. J Am Coll Cardiol. 2014;64(15):1568–1576. doi:10.1016/j.jacc.2014.06.1198.
45.
BradburyAWHallJAPopplewellMA, et al. Plain versus drug balloon and stenting in severe ischaemia of the leg (BASIL-3): open label, three arm, randomised, multicentre, phase 3 trial. BMJ. 2025;388:e080881. doi:10.1136/bmj-2024-080881.
46.
GuoZGuoJWuS, et al. Comparative efficacy and safety of different balloon angioplasty procedures for infrapopliteal artery lesions in chronic limb-threatening ischemia patients: a systematic review and network meta-analysis [published online ahead of print November 23, 2024]. J Endovasc Ther. doi:10.1177/15266028241292954.
47.
HaddadSEShishaniJMQtaishI, et al. One year primary patency of infrapopliteal angioplasty using drug- eluting balloons: single center experience at King Hussein medical center. J Clin Imaging Sci. 2017;7:31. doi:10.4103/jcis.JCIS_34_17.
48.
JiaXZhuangBWangF, et al. Drug-coated balloon angioplasty compared with uncoated balloons in the treatment of infrapopliteal artery lesions (AcoArt II-BTK). J Endovasc Ther. 2021;28:215–221. doi:10.1177/1526602820969681.
49.
LiistroFPortoIAngioliP, et al. Drug-eluting balloon in peripheral intervention for below the knee angioplasty evaluation (DEBATE-BTK): a randomized trial in diabetic patients with critical limb ischemia. Circulation. 2013;128(6):615–621. doi:10.1161/CIRCULATIONAHA.113.001811.
50.
SunGLiuJJiaX, et al. Long-term outcomes of the AcoArt II-BTK trial: drug-coated balloon angioplasty compared with uncoated balloons for the treatment of infrapopliteal artery lesions [published online ahead of print December 18, 2024]. J Endovasc Ther. doi:10.1177/15266028241304303.
51.
GouefficYBrodmannMDelooseK, et al. Drug-eluting devices for lower limb peripheral arterial disease. Eurointervention. 2024;20(18):e1136–e1153. doi:10.4244/EIJ-D-23-01080.
52.
LukacsRAWeisshaarLITornyosD, et al. Comparing endovascular approaches in lower extremity artery disease: insights from a network meta-analysis. J Clin Med. 2024;13(4):1024. doi:10.3390/jcm13041024.
53.
ThanigaimaniSSunDAhmadU, et al. Network meta-analysis of randomised controlled trials comparing the outcomes of different endovascular revascularisation treatments for infra-inguinal peripheral arterial disease causing chronic limb threatening ischaemia. Eur J Vasc Endovasc Surg. 2024;68(2):246–254. doi:10.1016/j.ejvs.2024.05.014.
54.
GeraghtyP. 12-Month Lutonix BTK IDE Trial Results Presented at LINC 2020. Vascular Disease Management; 2020.
55.
KatsanosKKitrouPSpiliopoulosS, et al. Comparative effectiveness of plain balloon angioplasty, bare metal stents, drug-coated balloons, and drug-eluting stents for the treatment of infrapopliteal artery disease: systematic review and Bayesian network meta-analysis of randomized controlled trials. J Endovasc Ther. 2016;23(6):851–863. doi:10.1177/1526602816671740.
56.
ZhangCYinG.Safety of paclitaxel-coated devices in the femoropopliteal arteries: a systematic review and meta-analysis. PLoS ONE. 2022;17(10):e0275888. doi:10.1371/journal.pone.0275888.
57.
SiablisDKitrouPMSpiliopoulosS, et al. Paclitaxel-coated balloon angioplasty versus drug-eluting stenting for the treatment of infrapopliteal long-segment arterial occlusive disease: the IDEAS randomized controlled trial. JACC Cardiovasc Interv. 2014;7(9):1048–1056. doi:10.1016/j.jcin.2014.04.015.
58.
VarcoeRLDeRubertisBGKolluriR, et al. Drug-eluting resorbable scaffold versus angioplasty for infrapopliteal artery disease. N Engl J Med. 2024;390(1):9–19. doi:10.1056/NEJMoa2305637.
59.
RastanABrechtelKKrankenbergH, et al. Sirolimus-eluting stents for treatment of infrapopliteal arteries reduce clinical event rate compared to bare-metal stents: long-term results from a randomized trial. J Am Coll Cardiol. 2012;60(7):587–591. doi:10.1016/j.jacc.2012.04.035.
60.
BosiersMScheinertDPeetersP, et al. Randomized comparison of everolimus-eluting versus bare-metal stents in patients with critical limb ischemia and infrapopliteal arterial occlusive disease. J Vasc Surg. 2012;55(2):390–398. doi:10.1016/j.jvs.2011.07.099.
61.
ScheinertDKatsanosKZellerT, et al. A prospective randomized multicenter comparison of balloon angioplasty and infrapopliteal stenting with the sirolimus-eluting stent in patients with ischemic peripheral arterial disease: 1-year results from the ACHILLES trial. J Am Coll Cardiol. 2012;60(22):2290–2295. doi:10.1016/j.jacc.2012.08.989.
62.
AlmasriJAdusumalliJAsiN, et al. A systematic review and meta-analysis of revascularization outcomes of infrainguinal chronic limb-threatening ischemia. Eur J Vasc Endovasc Surg. 2019;58(1S):S110–S119. doi:10.1016/j.ejvs.2019.04.013.
63.
van ReijenNSHensingTSantemaTKB, et al. Outcomes of conservative treatment in patients with chronic limb threatening ischaemia: a systematic review and meta-analysis. Eur J Vasc Endovasc Surg. 2021;62(2):214–224. doi:10.1016/j.ejvs.2021.01.005.
64.
RutherfordRBBakerJDErnstC, et al. Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg. 1997;26(3):517–538. doi:10.1016/s0741-5214(97)70045-4.
65.
BonacaMPBauersachsRMAnandSS, et al. Rivaroxaban in peripheral artery disease after revascularization. N Engl J Med. 2020;382(21):1994–2004. doi:10.1056/NEJMoa2000052.
66.
StonerMCCalligaroKDChaerRA, et al. Reporting standards of the society for vascular surgery for endovascular treatment of chronic lower extremity peripheral artery disease. J Vasc Surg. 2016;64(1):e1–e21. doi:10.1016/j.jvs.2016.03.420.
67.
GilesKAPomposelliFBSpenceTL, et al. Infrapopliteal angioplasty for critical limb ischemia: relation of TransAtlantic InterSociety consensus class to outcome in 176 limbs. J Vasc Surg. 2008;48(1):128–136. doi:10.1016/j.jvs.2008.02.027.
68.
RomitiMAlbersMBrochado-NetoFC, et al. Meta-analysis of infrapopliteal angioplasty for chronic critical limb ischemia. J Vasc Surg. 2008;47(5):975–981. doi:10.1016/j.jvs.2008.01.005.
69.
BalzerJOKhanVThalhammerA, et al. Below the knee PTA in critical limb ischemia results after 12 months: single center experience. Eur J Radiol. 2010;75(1):37–42. doi:10.1016/j.ejrad.2010.04.014.
70.
LoRCDarlingJBensleyRP, et al. Outcomes following infrapopliteal angioplasty for critical limb ischemia. J Vasc Surg. 2013;57(6):1455–1463. doi:10.1016/j.jvs.2012.10.109.
71.
ShishehborMHHammadTAZellerT, et al. An analysis of IN.PACT DEEP randomized trial on the limitations of the societal guidelines-recommended hemodynamic parameters to diagnose critical limb ischemia. J Vasc Surg. 2016;63(5):1311–1317. doi:10.1016/j.jvs.2015.11.042.
72.
FerraresiRUcciACasiniA, et al. GLASS(Global limb anatomic staging system): a critical appraisal. J Cardiovasc Surg. 2021;62(2):98–103. doi:10.23736/S0021-9509.20.11696-3.
73.
GiannopoulosSVarcoeRLLichtenbergM, et al. Balloon angioplasty of infrapopliteal arteries: a systematic review and proposed algorithm for optimal endovascular therapy. J Endovasc Ther. 2020;27(4):547–564. doi:10.1177/1526602820931488.
74.
HagaMShindoSMotohashiS, et al. Early evaluation of the infrainguinal revascularization strategy selection tool of the global vascular guidelines for chronic limb-threatening ischemia patients. J Vasc Surg. 2021;74(4):1253–1260. doi:10.1016/j.jvs.2021.04.034.
75.
StrømMKongeLLönnL, et al. Amputation-free survival after crural percutaneous transluminal angioplasty for critical limb ischemia. Scand J Surg. 2016;105(1):42–48. doi:10.1177/1457496915571403.
76.
UtsunomiyaMIidaOYamauchiY, et al. Influence of repeat intervention on the risk of major amputation after infrapopliteal angioplasty for critical limb ischemia. J Endovasc Ther. 2016;23(5):710–716. doi:10.1177/1526602816656831.
77.
GornikHLAronowHDGoodneyPP, et al. 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS guideline for the management of lower extremity peripheral artery disease: a report of the American college of cardiology/American heart association joint committee on clinical practice guidelines. Circulation. 2024;149(24):e1313–e1410. doi:10.1161/CIR.0000000000001251.
78.
VenermoMSpryngerMDesormaisI, et al. Editor’s choice—follow-up of patients after revascularisation for peripheral arterial diseases: a consensus document from the European society of cardiology working group on aorta and peripheral vascular diseases and the European society for vascular surgery. Eur J Vasc Endovasc Surg. 2019;58(5):641–653. doi:10.1016/j.ejvs.2019.06.017.
79.
ZierlerREJordanWDLalBK, et al. The society for vascular surgery practice guidelines on follow-up after vascular surgery arterial procedures. J Vasc Surg. 2018;68(1):256–284. doi:10.1016/j.jvs.2018.04.018.
80.
IpemaJHuizingESchreveMA, et al. Editor’s choice—drug coated balloon angioplasty vs. standard percutaneous transluminal angioplasty in below the knee peripheral arterial disease: a systematic review and meta-analysis. Eur J Vasc Endovasc Surg. 2020;59(2):265–275. doi:10.1016/j.ejvs.2019.10.002.
81.
CaiHDongJYeY, et al. Safety and efficacy of drug-coated balloon in the treatment of below-the-knee artery: a meta-analysis. J Surg Res. 2022;278:303–316. doi:10.1016/j.jss.2022.04.055.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
